Johnson & Johnson (JNJ) Stake Increased by Argus Investors Counsel Inc.

Argus Investors Counsel Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,124 shares of the company’s stock after buying an additional 3,951 shares during the quarter. Johnson & Johnson comprises about 1.9% of Argus Investors Counsel Inc.’s holdings, making the stock its 22nd biggest holding. Argus Investors Counsel Inc.’s holdings in Johnson & Johnson were worth $4,262,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of JNJ. BlackRock Inc. raised its position in Johnson & Johnson by 4.7% in the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Johnson & Johnson by 2.0% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,761,934 shares of the company’s stock valued at $3,813,993,000 after purchasing an additional 590,069 shares during the last quarter. Fisher Asset Management LLC raised its position in Johnson & Johnson by 3.8% in the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock valued at $1,591,811,000 after purchasing an additional 478,982 shares during the last quarter. Boston Partners raised its position in Johnson & Johnson by 68.7% in the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Johnson & Johnson by 4.7% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,590,694 shares of the company’s stock valued at $1,100,897,000 after purchasing an additional 383,040 shares during the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

Shares of Johnson & Johnson stock opened at $133.87 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The firm has a market cap of $370.70 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 2.19 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the prior year, the company posted $1.83 EPS. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 8.14 earnings per share for the current year.

In other news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

JNJ has been the subject of several research reports. Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target for the company. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, July 13th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $143.91.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Put Option

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply